Clinical trials: Intravitreal Injections
Exudative Age-Related Macular Degeneration
Evaluation of AL-78898A in Exudative Age-Related Macular Degeneration
The primary purpose of this study was to demonstrate a biological effect of AL-78898A, as measured by change (reduction) in central subfield (CSF) retinal thickness 4 weeks after a single intravitreal injection, as compared to…
- Trial name
- RACE (NCT01157065)
- Testing
- AL-78898A, Ranibizumab
- Where
- United States
- Volunteers
- 99 people
- Sponsor
- Alcon Research
Neovascular Age-related Macular Degeneration
Evaluation the Pharmacokinetics,Safety,Tolerability of Single Intravitreal Injection RC28-E in Subjects With Wet Age-Related Macular Degeneration
The purpose of this first-in-human study is to evaluate the safety, tolerability and pharmacokinetics of single intravitreous injections,single ascending doses, of RC28-E(a chimeric decoy receptor trap fusion protein by dual…
- Trial name
- NCT03777254
- Testing
- RC28-E
- Where
- China
- Volunteers
- 12 people
- Sponsor
- RemeGen Co., Ltd.
Retinitis Pigmentosa
Safety and Efficacy of Intravitreal Injection of Human Retinal Progenitor Cells in Adults With Retinitis Pigmentosa
This study evaluates the changes in visual function at 12 months following a single injection of human retinal progenitor cells compared to sham treated controls in a cohort of adult subjects with RP.
- Trial name
- NCT03073733
- Testing
- human retinal progenitor cells, Mock injection
- Where
- 3 sites in United States
- Volunteers
- 84 people
- Sponsor
- jCyte, Inc
Macular Degeneration, Age-Related Maculopathies
Safety and Tolerability Study of AAV2-sFLT01 in Patients With Neovascular Age-Related Macular Degeneration (AMD)
This Phase 1 clinical research study will examine the safety and tolerability of an experimental gene transfer agent, AAV2-sFLT01, in patients with Neovascular Age-Related Macular Degeneration (AMD).
- Conditions
- Macular Degeneration, Age-Related Maculopathies, Age-Related Maculopathy, Maculopathies, Age-Related
- Trial name
- NCT01024998
- Testing
- AAV2-sFLT01
- Where
- 4 sites in United States
- Volunteers
- 19 people
- Sponsor
- Genzyme, a Sanofi Company
Diabetes Mellitus, Macular Edema
Intravitreal Aflibercept Injection in Vision Impairment Due to DME
To determine the efficacy of intravitreally (IVT) administered VEGF Trap-Eye on the best-corrected visual acuity (BCVA) assessed by the early treatment diabetic retinopathy study (ETDRS) chart in subjects with diabetic macular…
- Trial name
- VIVID-DME (NCT01331681)
- Testing
- VEGF Trap-Eye (BAY86-5321), Macular Laser Photocoagulation (Control)
- Where
- 73 sites in Australia, Austria and 9 more
- Volunteers
- 406 people
- Sponsor
- Bayer
Macular Edema
Efficacy and Safety of Three Different Aflibercept Regimens in Subjects With Diabetic Macular Edema (DME)
To evaluate the efficacy of long-term treatment with 2 mg aflibercept via different intravitreal (IVT) treatment regimens to participants with DME pretreated with 2 mg aflibercept every 8 weeks after 5 initial monthly injections…
- Trial name
- VIOLET (NCT02818998)
- Testing
- Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)
- Where
- 64 sites in Austria, Canada and 12 more
- Volunteers
- 463 people
- Sponsor
- Bayer
Diabetic Retinopathy
A Safety and Efficacy Study of Vitreosolve® for Non-Proliferative Diabetic Retinopathy Subjects
The purpose of this study is to determine the safety and efficacy of Vitreosolve® in diabetic retinopathy patients.
- Trial name
- NCT00908778
- Testing
- Vitreosolve
- Where
- 5 sites in India, Mexico
- Volunteers
- 160 people
- Sponsor
- Vitreoretinal Technologies, Inc.
Neovascular Age-related Macular Degeneration (nAMD)
Study of the Safety of Use of Intravitreal SOK583A1 Provided in a Vial Kit
This is a single-arm, open-label study where all patients will receive a single injection of SOK583A1 (40 mg/mL) provided in a vial kit at Baseline. The total study duration for the individual participant is approximately 31 days.
- Trial name
- NCT05282004
- Testing
- SOK583A1
- Where
- 5 sites in United States
- Volunteers
- 36 people
- Sponsor
- Sandoz
Age Related Macular Degeneration
Evaluate the Safety and Efficacy of HLX04-O in Subjects With wAMD
This study will evaluate the safety, tolerability, pharmacokinetics and preliminary efficacy of HLX04-O administered every 4 weeks in participants with wet age-related macular degeneration (wAMD)
- Trial name
- NCT04993352
- Testing
- recombinant anti-vascular endothelial growth factor (VEGF) humanized monoclonal antibody ophthalmic injection
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Shanghai Henlius Biotech
Open Angle Glaucoma
Study of ANX007 in Participants With Primary Open-angle Glaucoma
This is a double-masked, randomized, sham-controlled study evaluating two dose levels of ANX007 vs sham, administered as repeat Intravitreal (IVT) injections in patients with Primary Open-angle Glaucoma.
- Trial name
- NCT04188015
- Testing
- 2.5mg ANX007, 5.0mg ANX007
- Where
- 2 sites in United States
- Volunteers
- 17 people
- Sponsor
- Annexon, Inc.
Focal Vitreomacular Adhesion
Safety and Efficacy Study of Microplasmin in for Non-Surgical Treatment of Focal Vitreomacular Adhesion
This study will evaluate the safety and efficacy of Microplasmin administered as an intravitreal injection, in subjects with focal vitreomacular adhesion.
- Trial name
- MIVI-8 (NCT01055535)
- Testing
- Microplasmin
- Where
- Belgium
- Volunteers
- 17 people
- Sponsor
- ThromboGenics
Retinal Detachment
Study of Denufosol (INS37217) in Subjects With Rhegmatogenous Retinal Detachment
The purpose of this study is to test if denufosol will remove the fluid build-up in the eye so that the retina can be re-attached without invasive surgery.
- Trial name
- NCT00083967
- Testing
- denufosol tetrasodium (INS37217) Intravitreal Injection
- Where
- 33 sites in United States
- Volunteers
- 23 people
- Sponsor
- Merck Sharp & Dohme LLC
Age-Related Macular Degeneration, Retinal Vein Occlusion
Extension Study to Gather Data on Effect of Macugen on the Corneal Endothelium
This study was conducted because the FDA requested clinical information on potential effects of intravitreal injections of Macugen (pegaptanib sodium injection) on the corneal endothelium from a 1-year (minimum) post-approval…
- Conditions
- Age-Related Macular Degeneration, Retinal Vein Occlusion, Diabetic Macular Edema
- Trial name
- NCT01573572
- Testing
- pegaptanib sodium injection
- Where
- 4 sites in United States
- Volunteers
- 131 people
- Sponsor
- Bausch & Lomb Incorporated
Macular Edema, Cystoid, Retinal Vein Occlusion
The Standard Care vs. COrticosteroid for REtinal Vein Occlusion (SCORE) Study
The SCORE Study will compare the effectiveness and safety of standard care to intravitreal injection(s) of triamcinolone for treating macular edema (swelling of the central part of the retina) associated with central retinal vein…
- Trial name
- SCORE (NCT00105027)
- Testing
- Standard Care, intravitreal triamcinolone injection
- Where
- United States
- Volunteers
- 682 people
- Sponsor
- The Emmes Company, LLC
Diabetic Macular Edema
Pegaptanib Sodium Compared to Sham Injection in Patients With DME Involving the Center of the Macula
The purpose of the study is to determine whether pegaptanib sodium (Macugen) is safe and effective in slowing the leakage of fluid within the retina and thereby stabilizing or improving vision when compared to placebo injections.
- Trial name
- NCT00040313
- Testing
- pegaptanib sodium (Macugen)
- Sponsor
- Eyetech Pharmaceuticals
Wet Age-related Macular Degeneration
Observational Study to Assess Intravitreal Aflibercept Injections Used in a "Treat and Extend" Regimen in Treatment-naïve Wet Age-related Macular Degeneration Patients
The purpose of this observational study lies in the analysis of a treat-and-extend injection scheme with intravitreal aflibercept (i.e.
- Trial name
- ASTERIA (NCT03382587)
- Testing
- Aflibercept (Eylea, BAY86-5321)
- Where
- Switzerland
- Volunteers
- 163 people
- Sponsor
- Bayer
Macular Degeneration
Open Label Study for the Evaluation of Tolerability of Five Dose Levels of Cand5
To establish the tolerability and preliminary efficacy of Cand5 by a single intravitreal injection in patients with wet age-related macular degeneration.
- Trial name
- NCT00722384
- Testing
- bevasiranib
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- OPKO Health, Inc.
Macular Degeneration
Safety and Pharmacokinetics of Abicipar Pegol Intravitreal Injections in Japanese Patients With Neovascular AMD
This study will evaluate the safety and to characterize the systemic pharmacokinetics of free and vascular endothelial growth factor (VEGF)-bound abicipar following multiple monthly intravitreal injections of abicipar in Japanese…
- Trial name
- PINE (NCT03335852)
- Testing
- Abicipar pegol
- Where
- 5 sites in Japan
- Volunteers
- 11 people
- Sponsor
- Allergan
Vitreous Hemorrhage, Diabetic Retinopathy
Safety and Efficacy Study of Vitrase for Clearance of Severe Vitreous Hemorrhage
The purpose of this study is to determine if intravitreal injection of Vitrase (ovine hyaluronidase) clears vitreous hemorrhage
- Trial name
- NCT00198497
- Testing
- Vitrase
- Where
- 58 sites in Australia, Brazil and 7 more
- Volunteers
- 510 people
- Sponsor
- Bausch & Lomb Incorporated
Retinitis Pigmentosa (RP)
Safety of a Single, Intravitreal Injection of Human Retinal Progenitor Cells (jCell) in Retinitis Pigmentosa
This study evaluates the safety and potential activity of a single dose of live human retinal progenitor cells (jCell) administered to adults with retinitis pigmentosa.
- Trial name
- NCT02320812
- Testing
- human retinal progenitor cells
- Where
- 2 sites in United States
- Volunteers
- 28 people
- Sponsor
- jCyte, Inc